Federation Des Caisses Desjardins Du Quebec Tcr2 Therapeutics Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

  • $18.9 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2024
SELL
$0.0 - $1.98 $0 - $990
-500 Closed
0 $0
Q1 2022

Aug 14, 2024
BUY
$2.4 - $4.71 $1,200 - $2,355
500 New
500 $1.38 Million
Q4 2021

Aug 30, 2024
BUY
$4.58 - $8.34 $1,145 - $2,085
250 Added 100.0%
500 $2.33 Million
Q3 2021

Aug 30, 2024
BUY
$8.44 - $18.35 $2,110 - $4,587
250 New
250 $2.13 Million
Q2 2020

Aug 30, 2024
SELL
$6.51 - $16.85 $1,953 - $5,055
-300 Closed
0 $0
Q1 2020

Aug 30, 2024
BUY
$6.01 - $16.01 $1,803 - $4,803
300 New
300 $2.32 Million

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email